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Ganoderma is a basidiomycete white rot fungus which has been used for medicinal purposes for centuries particularly in China, Japan
and Korea. A great deal of work has been carried out on Ganoderma lucidum. The common names for preparations include Lingzhi,
Munnertake, Sachitake, Reishi and Youngzhi. This review collates the publications detailing activities and compounds by representative
species whilst considering the most valid claims of eﬀectiveness. The biological activities reported of preparations from Ganoderma are
remarkable and given most emphasis herein as distinct from structure/activity information. The metabolites consist of mainly polysac-
charides and terpenoids. Many are activities against the major diseases of our time and so the present review is of great importance. The
list of eﬀects is huge ranging from anti-cancer to relieving blockages of the bladder. However, the reports have not all been tested sci-
entiﬁcally with the convincing evidence is reserved for assays of pure compounds. It is a prime example of an ancient remedy being of
great relevance to the modern era. There does appear to be an assumption that the therapeutic eﬀects attributed to the fungus have been
proven. The next step is to produce some eﬀective medicines which may be hampered by problems of mass production.
 2006 Elsevier Ltd. All rights reserved.
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Ganoderma is a proliﬁc producer of novel ‘‘mycochemi-
cals’’. The quantity of information on the fungus in this
respect is quite remarkable; hence this is an extensive
review. However, there is an uneasy combination of the
mythical, pseudo-science and science and deciding one
from the other requires experience. The organism is a white
rot which is involved in the fundamental process of ligno-
cellulose degradation in Nature, although this aspect will
not be considered. An image of a Ganoderma specimen is
provided in Fig. 1 and appears to be G. applanatum from
the morphology alone. The Chinese, inter alia, have used
preparations as medicines from a similar or identical fun-
gus, for millennia (cited as early as 100 BC) and have given
the organism the name ‘‘Lingzhi’’. In Japan the names
include Munnertake, Sachitake and Reishi, whereas in
Korea it has the name Youngzhi. However, whether this
and any particular species of Ganoderma represent the
same entity and throughout all periods in history is ques-
tionable. The taxonomic situation within Ganoderma is
unclear as the species and genus concepts are confused.
For example, similar fungi are found in Fomes, Polyporus
and Tomophagus.
‘‘Lingzhi’’ is the Chinese name given to the basiocarps
(my preferred name) of Ganoderma as isolated in that vast
and diverse country. However, there is a tendency for
authors in the scientiﬁc literature to refer to such names
making deﬁnitive conclusions more diﬃcult (see Huie and
Di, 2004). The preparation was and is considered to have
healing properties to the body and mind: ‘‘Lingzhi’’ is still
revered by some. The preparation does indeed contain cer-
tain bioactive ingredients (such as triterpenes and polysac-
charides) that might be beneﬁcial for the prevention and
treatment of a variety of ailments. Remarkably, these
include such very important diseases such as hypertension,
diabetes, hepatitis, cancers, and AIDS. These types of bio-
medical investigations have been conducted predominately
in China, Korea, Japan and the United States of America
and so are extensive. It is unclear why other countries are
not more involved.Fig. 1. A typical Ganoderma basidiocarp.Research, quality assurance and control of ‘‘Lingzhi’’
products depend on the isolation/puriﬁcation of active
ingredients and analytical/preparative separations (Huie
and Di, 2004). A practical classiﬁcation of the fungus is
required to understand more clearly what the fungus repre-
sents. In addition, research is necessary on the physiology
of production of the active metabolites to enable yields to
be optimised in solid or liquid substrate bioreactors –
assuming they can be so produced.
Preparations referred to as ‘‘Lingzhi’’ were/are used
widely as a health supplement and ‘‘herbal’’ medicine
worldwide. Of course, the fungus is not a herb (which are
plants) and calling it such simply adds to the confusions
surrounding names. A company in the USA has a web site
with numerous Ganoderma products which makes extraor-
dinary claims for medicinal properties (http://www.fungi.-
com/). This raises issues of accreditation and validity.
However, strapped-for-cash culture collections will look
enviously at the commercial potential. Employing my com-
puter search engine gave numerous ‘‘hits’’ from organisa-
tions selling such preparations which must surely be of
concern to those in search of valid data.
As indicated previously, there are issues that require to
be addressed in relation to the fungus: What is Ganoderma?
How does it relate to Fomes, Polyporus, and Tomophagus?
What constitute the preparations with non-Latinised names
that are often referred to (e.g. Lingzhi, Songshan lingzhi,
Reishi)? After all, these are the ancient medicines on which
all the new research and interest are based. Have voucher
specimens of Ganoderma been placed in culture collections
with international accreditation, and are they available to
others (see Paterson, 2005)? How useful is the information
in obscure journals? Using only one sample for species rec-
ognition as has occurred (e.g. Di et al., 2003) and is invalid
as assessments of variation cannot be obtained.
For example, a G. lucidum has been worked on exten-
sively and yet was obtained from the family-owned com-
pany mentioned previously (see Ziegenbein et al., 2006).
What degree of scientiﬁc accreditation applies to this pri-
vate enterprise? The same questions can be asked of other
culture collections, whether public or private, where high
quality accessions, preservation and identiﬁcations may
not apply: A culture collection in China will not necessarily
have the equivalent standards to one in the USA.
‘‘Lingzhi’’ has been examined predominantly for bioac-
tive triterpenes and polysaccharides. It is perhaps surpris-
ing that other classes of intrinsically secondary
metabolites have not been found. For example, polyketides
and shikimic acid pathway metabolites are not well repre-
sented. A point to consider is that the fungus may trans-
form compounds from the host on which it was isolated
and not be able to produce the compounds per se. This
may be true particularly of lignin-derived compounds as
the white rot fungi degrade lignin to monomeric phenols
and further to CO2 and H2O for energy (Leonowicz
et al., 1999) which will have ramiﬁcations for mass produc-
tion of treatments.
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scientiﬁc papers (cf. Huie and Di, 2004) as it is imprecise
and the Latin names should prevail. I will tend to use
inverted commas when referring to it as a compromise.
‘‘Lingzhi’’ has been used for the treatment of migraine,
hypertension, arthritis, bronchitis, asthma, anorexia, gas-
tritis, haemorrhoids, diabetes, hypercholesterolaemia,
nephritis, dysmenorrhoea, constipation, lupus erythemato-
sis, hepatitis, and cardiovascular problems. One can only
wonder how the treatments were assessed as being eﬀective.
It is claimed to possess (a) anti-cancer (including leukae-
mia), (b) anti-ageing and (c) anti-microbial/viral activities
including anti-human immunodeﬁciency virus (HIV).
Additionally, the presence of neuroactive compounds in
the extracts of ‘‘Lingzhi’’ that mediated the neuronal diﬀer-
entiation and neuroprotection of rat PC12 cells has also
been demonstrated recently (Huie and Di, 2004). This all
seems like very good news indeed as even one of these
eﬀects would be remarkable if some new prescribed medi-
cines were produced. Extraordinary claims such as these
needs to have equivalent evidence to prove that they are
factual.
Furthermore, Ganoderma is not a herb as mentioned
previously: It is a complex fungus which has had very sig-
niﬁcant interactions with human beings over the centuries.
The label ‘‘herb’’ needs to be avoided. Fungi form a sepa-
rate kingdom from plants and are closer to animals in an
evolutionary sense. These deﬁnitions are important. For
example, Ganoderma is not likely to contain lignin but this
is what is implied in Huie and Di (2004) in an interpreta-
tion of how an enzyme-based extraction procedure is eﬀec-
tive. The enzyme was claimed to break bonds between
cellulose and lignin hence permitting the extraction of the
desired material. And so the rational for the extraction pro-
cedure with enzymes was wrong from the initial assump-
tion. The following review will consider how the fungus
became to be known as an ancient remedy for ailments
and what the latest developments have been. Extensive ref-
erences are provided because of the huge claims beings
made of the biomedical activities of Ganoderma.2. ‘‘Herbal’’ medicinal Ganoderma
Sliva (2006) and Stanley et al. (2005) mention that G.
lucidum is a popular medicinal mushroom, and has been
used in traditional Chinese medicine (TCM) in Asian coun-
tries over the past two millennia. The regular consumption
was/is believed to preserve human vitality and to promote
longevity. The fungus has been used for the prevention,
or treatment, of numerous diseases including cancer
although whether it was eﬀective is presumably unknown.
Western medicine began to study natural products from
TCM and the popularity of herbal therapies for the treat-
ment of cancer has increased in the USA. Of course, Gano-
derma is a fungus and not a herb. Scientiﬁc elucidation of
mechanisms responsible for the biological eﬀects of thesenatural products would indicate if they were valid alterna-
tives, or adjuvant cancer therapies; as would well-con-
ducted therapeutic trials.
Furthermore, Chen et al. (2006) in an extensive paper
mention that many ‘‘herbal’’ medicines are used widely as
immuno-modulators in Asian countries. G. lucidum is one
of the most used ‘‘herbs’’ in Asia and preclinical studies
have established that the polysaccharide fractions have
potent eﬀects. Also, one wonders what ‘‘established’’
means here – is it proven? As mentioned, clinical evidence
for this is scarce. Pero et al. (2005) state that, the combina-
tion of nutritional supplements to achieve synergistic ben-
eﬁt is a common practice in the nutraceutical industry.
However, establishing added health beneﬁt from a combi-
nation of natural ingredients is often assumed, untested
and without regard to the principle of metabolic competi-
tion between the active components (see Aydemir, 2002).
The dried powder is currently used worldwide in the
form of dietary supplements. Stanley et al. (2005) have
demonstrated that G. lucidum induces apoptosis, inhibits
cell proliferation, and suppresses cell migration of highly
invasive human prostate cancer cells PC-3. However, the
molecular mechanism(s) responsible for the inhibitory
eﬀects have not been fully elucidated. Hajjaj et al. (2005)
state that G. lucidum is a medicinal fungus belonging to
the Polyporaceae family and is know in Japan as Reishi.
Furthermore, Mu¨ller et al. (2006) emphasise that over
many centuries, ‘‘herbal’’ remedies have treated a variety
of ailments and the empirical/observational approach has
produced a number of leads for formulated medicines.
Lin et al. (2006) refer to G. tsugae as the Chinese mush-
room Songshan lingzhi, which is cultivated in Taiwan
and used extensively to treat diseases. Johnston (2005)
alludes to the fact that G. lucidum is used in TCM for the
treatment of cancers. In truth, the fungus must be one of
the most convincing examples of ancient folk remedies
being translated into new drug leads, and may represent
an excellent paradigm for the general principal. Screening
methods are very useful for assessing the constituents of
preparations before the isolation of compounds and this
is next presented.3. Metabolite proﬁling
Diﬀerentiation was possible of ‘‘Lingzhi’’ from several
other fungal crude drugs, such as hoelen, omphalia and pol-
yporus using TLC (Huie and Di, 2004). Ganoderic acids B
andC (see Fig. 1 for ganoderic acids) are unique constituents
of ‘‘Lingzhi’’. Incidentally, proﬁles in Ofodile et al. (2005)
indicated interesting diﬀerences between species, in addition
to the activities reported. TLC was applied for the diﬀeren-
tiation of species and unique triterpene patterns were
reported (Huie and Di, 2004). Samples could be grouped
into 18, which were similar clusters to those by HPLC. Sim-
ilarly, distinctive TLC patterns of triterpenes were obtained
from basidiocarps of G. lucidum and G. tsugae. A rapid agar
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carps of Ganoderma from oil palm were described in Miller
et al. (1995). Some of the metabolites were analysed by mass
spectrometry and did not appear to be lanostanoid com-
pounds. Di et al. (2003) used high-performance TLC for
the proﬁling of carbohydrates. This was the ﬁrst time this
approach had been used. Unique patterns were observed
between G. applanatum and G. lucidum. The analyses of
more strains and taxa are required generally (see Figs. 2
and 3).
Triterpenoid proﬁling for the chemotaxonomy of G. luci-
dum and related species has been demonstrated by HPLC.
Also, the determination and comparison of production
yields was obtained (Huie and Di, 2004). Samples could
be divided into 18 groups based on characteristics of the
HPLC pattern of triterpenoids, in good agreement with
morphological examination (and TLC). Rapid and eﬃcient
characterization of ‘‘Lingzhi’’ was obtained. In addition,Fig. 2. Chemical structure of some ganoderic acids.
Fig. 3. Chemical structure of some ganomastenols.strains of G. tsugae and G. lucidum were analysed for tri-
terpenoid of their basidiocarps. An HPLC procedure was
employed for the isolation of oxygenated triterpenoids from
crude extracts which has chemotaxonomic applications
(Lin and Shiao, 1987). Strain speciﬁc proﬁles were obtained
for G. lucidum (Nishitoba et al., 1986), and similar patterns
were observed by Hirotani et al. (1993a). Chen et al. (1999)
deduced some strains were similar and yet others diﬀerent.
The proﬁles provide useful chemotaxonomic data and
activity/quality information.
Fourier transform infrared absorption and HPLC for
the classiﬁcation/identiﬁcation of commercial G. lucidum
and G. tsugae products into three diﬀerent types (cultured
mycelia, fruiting bodies and mixed mycelia/fruiting bodies)
are also reported. Other workers have isolated nine triterp-
enoids from the basidiocarps of G. tsugae: ganoderic acids
E, C5, C6, G and ganoderenic acid D (see Table 1) were
analysed for the ﬁrst time by HPLC. A method for deter-
mining ganoderic acid B in diﬀerent parts of G. lucidum
has been validated. The pilei (caps) were found to be the
optimal source of ganoderic acid B, followed by the stipes
(stems), and the spores were the poorest source. Similarly,
the determination of ganoderic acid A, ganoderic acid C,
ganoderic acid D and ganoderic acid E in cultured and wild
G. lucidum was achieved, and this method was claimed to
be highly suitable for the quality control of ‘‘herbal’’ for-
mulations containing ‘‘Lingzhi’’ (Huie and Di, 2004). A
validated method was reported for the simultaneous analy-
sis of ganosporeric acid A, lucidenic acid A, ganoderic
acids B and C from G. lucidum. Interestingly, it was found
that the contents of four triterpenes in the fruiting bodies
were higher than that in the spores, and the triterpene con-
tents in the spores with a sporoderm-breaking rate of 85%
were found to be higher than those obtained from spores
having complete sporoderms. Another method was
described for the quantitative analysis of the ganoderic
alcohols and acids in the spores and ﬁve basidiocarps of
G. lucidum collected from diﬀerent countries. Six ganoderic
alcohols (lucidumols A and B, ganoderiols A and F, gano-
dermanontriol A, ganodermanondiol) were well separated.
Seven ganoderic acids also were well separated except for
ganoderic acids C1 and H on the same column using 2%
ethanol–acetonitrile (7:3) as the mobile phase. The results
indicated that the total triterpene content of the spores
was 5–20 times higher than that of the fruiting bodies (Huie
and Di, 2004). In contrast, other researchers have shown
that the spores were the poorest source of triterpenes.
Miller et al. (1995) describe an HPLC method using gradi-
ent solvent elution and UV detection which was used for
Ganoderma from oil palm, and it is desirable that the bio-
activities of oil palm isolates are determined.
Wang et al. (2006) analysed various Ganoderma species
for triterpenoids and the qualitative proﬁles of the species
indicate utility for separating the taxa. However, both G.
lucidum and G. sinense are the oﬃcial species of Lingzhi
recorded in the 2005 Chinese Pharmacopoeia and they
were considered to have the same therapeutic eﬀects. The
Table 1
A composite table comparing some polysaccharides and terpenoids/steroids from Ganoderma spp. reported in the journal Phytochemistry from the 1970s to present
Compounds Ganoderma species
Polysaccharides lucidum applanatum lipsiense carnosum sugae mastoporum neo-japonicum amboinense Indonesian sp. australe
Heteroglucan
PL-1 +
PL-2 +
Homoglucan
PL-3 +
Terpenoids and steroids
(24S)-24-methylcholesta-7,16-dien-3b-ol +
(24n)-24-methyl-5a-cholest-7-en-3b-ol +
(24S)-24-methyl-5a-cholest-7,16-dene-3b-ol +
24-Methylcholesta-7,22-dien-3b-ol + +
24-Methylcholesta-5,7,22-trien-3b-ol ergosterol + +
24-Methylcholest-7-en-3b-ol + +
(24S)-24-methyl-5a-cholest-7-ene-3b ol (Ia) +
Sesquiterpene ()-7-hydroxycalamenene +
Friedelin (terpene) +
Alnusenone +
Friedoolean-5-en-3one +
Ergosta-5,7,22-triene-3b-ol +
Ergosterol + + + +
Ergosta-7,22-diene-3-one +
Ergosterol peroxide1 +
Ergosterol peroxide + +
Ergosta-7,22-diene-3b-yl palmitate +
Ergosta-7,22-diene-3b-yl linoleate +
Ergosta-7,22-diene-3b-yl pentadecanoate +
Ergosta-7-diene-3b-yl linoleate +
Ergosta-7,22-dien-3b-ol + + +
Ergosta-7,22-dien-3-one +
Steroids: ergosta-7,22-dien-3b-ol, ergosta-7,22-dien-
3b-yl linoleate
+
Steroid: ergosta-7,22-dien-3b-yl palmitate +
Steroid: 2b,3a,9a-trihydroxyergosta-7,22-diene +
Steroid: 5a,8a-epidioxyergosta-6,9(11),22-trien-3b-ol +
Triterpenoid esters
Ganoderic acid A, B, C1, H +
Ganoderic acid N? +
Ganoderic acid methyl ester + +
Ganoderic derivatives Sekishi/Shishi
strains +,
Kokushi 
Ganoderic acid V1: (24E)-3b,20n-dihydroxy-7,11,15-
trioxo-5a-lanosta-8,24-dien-26-oic acid
+ Shishi strain
Ganoderic acid V1: (24E)-3b,20n-dihydroxy-7,11,15-
trioxo-5a-lanosta-8,24-dien-26-oic acid
+ Shishi strain
Triterpenoids Ten ganoderic acid, ganoderenic acid and
lucidenic acid derivatives
+
(continued on next page)
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Table 1 (continued)
Compounds Ganoderma species
Polysaccharides lucidum applanatum lipsiense carnosum sugae mastoporum neo-japonicum amboinense Indonesian sp. australe
Triterpenoids, ganoderic acid T, ganoderic acid S,
ganoderic acid R, ganoderic acid P, ganoderic acid Q,
ganoderic acid 0
+ mycelium
7-O-methyl-ganoderic acid 0 + mycelium
Ganoderenic acid A +
Ganoderenic acid D + +
Three linoleic acid steryl esters 3–5 +
Ganoderiols A, B, F +
Ganodermanontriol +
Cerevisterol +
3b-5a-dihydroxy-6b-methoxyergosta-7,22-diene +
Lanostane-type triterpene
26,27-Dihydroxylanosta-7,9(11),24-trien-3,16-dione +
Oleic acid methyl ester +
Glycerol trioleate +
Known lanostanoids
3b-hydroxy-5a-lanosta-8,24-dien-21-oic acid +
3-Oxo-5a-lanosta-8,24-dien-21-oic acid +
New lanostanoids
3a-acetoxy-5a-lanosta-8,24-dien-21-oic acid (tsugaric
acid A)
+
3a-acetoxy-16a-hydroxy-24n-methyl-5a-lanosta-8,25-dien-
21-oic acid (tsugaric acid B)
+
Cadinene sesquiterpenes
Ganomastenols A–D cultured mycelia and broth +
Polyoxygenated lanostanoid triterpenes
Applanoxidic acids E–H + (trop.
Indonesia)
Drimane-type sesquiterpenoids: cryptoporic acid H, I +
5 0-deoxy-5 0-methylsulphinyladenosine (both epimers) +
Oxygenated triterpenes: lanosta-7,9(11),24-trien-3a,15a-
dihydroxy-26-oic acid
+ mycelum
Polyhydroxyl steroid: 2b-methoxyl-3a,9a-
dihydroxyergosta-7,22-diene
+
Lanostanoid: ganoderic acid AM1, 3b-hydroxy-7,11,15,23-
tetraoxo-lanosta-8-en-26-oic acid
+
Lucidone A +
Two homolanostanoid triterpene hydroxyacids +
Carboxyacetylquercinic acid +
Lanosta-7,9(11),24-trien-3b,15a-dihydroxy-26-oic-acid + mycelium
Lanosta-7,9(11),24-trien-3b,22b-diacetoxy-15a-hydroxy-
26-oic acid
+ mycelium
Lanosta-7,9(11),24-trien-15a,22b-diacetoxy-3b-hydroxy-
26-oic acid
+ mycelium
Five new lanostanoid triterpenes +
Ergosterol derivative: ergosta-4,7,22-triene-3,6-dione + mycelium
3b,7b,15a-trihydroxy-11,23-dioxo-5a-lanost-8-en-26-oic
acid (ganoderic acid E)
+
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R. Russell M. Paterson / Phytochemistry 67 (2006) 1985–2001 1991average content of total triterpenoids in G. lucidum was 10
times higher than that in G. sinense, which indicated the
therapeutic eﬀects of these two species might be quite dif-
ferent. Therefore, they are recommended to be used as
two diﬀerent ‘‘herbal’’ medicines. Other obvious conclu-
sions would be that the compounds are not responsible
for the eﬀects, or that the eﬀects have not been scientiﬁcally
proven. This represents a common problem with some of
the data and interpretations reviewed herein. In general,
there appears to be an assumption that the therapeutic
eﬀects attributed to the fungus have been proven.
Polysaccharides of ‘‘Lingzhi’’ and ‘‘related species’’ have
been reported to be composed of a variety of monosaccha-
rides, including glucose, galactose, mannose, arabinose,
xylose, fucose, rhamnose, glucuronic acid and galacuronic
acid and could be separated by paper chromatography
(Huie and Di, 2004). The use of HPLC (or TLC) for carbo-
hydrates is reported rarely. High performance size exclu-
sion chromatography has been used for the quality
control of ‘‘Siwei Lingzhi’’. However, the chemicals from
Ganoderma have been described and this is considered in
the following section.4. Chemical constituents
Polysaccharides and triterpenes have been most thor-
oughly investigated from G. lucidum and related species.
However, sterols, lectins and proteins have also been
described. A list of the components which have been dis-
cussed in the journal Phytochemistry is provided in Table
1. This does not represent a chemotaxonomic treatment
as certain taxa have been analysed much more than others.
Nevertheless, some species produce the same compounds
and strain variation is revealed.
4.1. Triterpenes/triterpenoids
Cole et al. (2003) list four sesqueterpene compounds
from G. mastoporum: ganomastenol, ganomastenol B,
ganomastenol C, and ganomastenol D (see Table 1). Cole
and Schweikert (2003) include ergosterol; (24S)24-methyl-
5a-cholesta-7,16-dien-3b-ol; (24S)24-methylcholesta-7,22-
dien-3-one (Ergosta-7,22-dien-3-one) as C28 sterols from
G. applanatum. However, the names are also ‘‘equal to’’
four other Fomes species indicating a general systematic
problem. An equivalent situation exists for the C30 sterols
friedelin and alnusenone (friedoolean-5-en-3-one): These
are listed as being from G. applanatum. Oﬃcinalic acid
and senexdiolic acid (also C30s) are listed from F. oﬃcinalis
and F. senex, respectively. From G. lucidum only are pre-
sented (a) 40 ganoderic acids, (b) 14 ganoderiols, (c) 5
ganolucidic acids, and (d) 15 lucidenic acids. It would be
interesting to determine which other species (or genera)
produce these compounds. Understandably, the authors
put a disclaimer about the taxonomic veracity of the names
they use in the volumes.
1992 R. Russell M. Paterson / Phytochemistry 67 (2006) 1985–2001Furthermore, Akihisa et al. (2005) describe (a) two trit-
erpenoids: 20(21)-dehydrolucidenic acid A and methyl
20(21)-dehydrolucidenate A, and (b) ﬁve new 20-hydrox-
ylucidenic acids: 20-hydroxylucidenic acid D2, 20-hydrox-
ylucidenic acid F, 20-hydroxylucidenic acid E2, 20-
hydroxylucidenic acid N, and 20-hydroxylucidenic acid P
isolated from the basidiocarps of G. ludicum. Shim et al.
(2004) isolated four new lanostane-type triterpenes from
the methanol extract of the fruiting bodies of G. applana-
tum. These are: (a) 3b,7b,20,23n-tetrahydroxy-11,15-dioxo-
lanosta-8-en-26-oic acid, (b) 7b,20,23n-trihydroxy-3,11,15-
trioxolanosta-8-en-26-oic acid, (c) 7b,23n-dihydroxy-
3,11,15-trioxolanosta-8,20E(22)-dien-26-oic acid, and (d)
7b-hydroxy-3,11,15,23-tetraoxolanosta-8,20E(22)-dien-26-
oic acid methyl ester. The authors suggest that more of
these classes of compounds will be detected in future stud-
ies. The free sterols of G. applanatum and G. lucidum has
been determined to contain mainly (ergosterol) and 24-
methylcholesta-7,22-trien-3-ol. Also, the ﬁrst isolation of
8,9-epoxyergosta-5,22-dien-3,15-diol from G. lucidum was
reported (Huie and Di, 2004). So which biomedical activi-
ties have been described?5. Whole fungus/crude extracts bioactivities
Ganoderma have been investigated as anti-tumour and
antiviral agents and less so as anti-bacterial agents (Gao
et al., 2003). Anti-bacterial activity has been observed
against Gram-positive bacteria from the basidiocarp
extracts of G. lucidum (Kim et al., 1993) and G. orgonense
(Brian, 1951). Furthermore, Sudirman and Mujiyati (1997)
observed that seven Indonesian Ganoderma species inhib-
ited the growth of Bacillus subtilis. Yoon et al. (1994) inves-
tigated the additive eﬀect on the activity of an aqueous
extract of G. lucidum with four known antibiotics and
observed that the anti-bacterial activity increased. There
are relatively few studies on extracts from the liquid culti-
vated mycelium. Coletto and Mondino (1991) noted that
methanolic extracts of the mycelia and culture extracts of
G. recinaceum and G. lucidum inhibited B. subtilis. G. reci-
naceum also inhibited Staphylococcus aureus. Ethanolic
extracts from G. lucidum mycelium demonstrated signiﬁ-
cant anti-inﬂammatory eﬀects (Kendrick, 1985). Shieh
et al. (2001) concluded that the hepatic and renal protective
mechanism of G. lucidum might be because of its superox-
ide scavenging eﬀect. In addition, Lin et al. (1995) observed
that the greatest anti-hepatotoxic activity also exhibited the
highest free radical scavenging properties. Low molecular
weight aqueous fractions strongly inhibited multiplication
of HIV-1 (Kim et al., 1997). The basidiocarps of G. lucidum
lowered plasma cholesterol levels in rats (Kabir et al.,
1988).
In terms of the very recent literature, it is noted from the
company web site mentioned previously, that preparation
from ﬁve Ganoderma ‘‘species’’ are, ‘‘known to fortify the
immune system while exerting anti-inﬂammatory andanti-allergenic eﬀects’’. These carry a footnote saying that
the statements have not been evaluated by the US Food
and Drug Administration. This is mentioned here as a blur-
ring of scientiﬁc rigour which appears occasionally to be an
issue when dealing with Ganoderma. We need to get away
from this virtual-air-conditioned science and back to a sit-
uation where scientist actually collect and identify their
own specimens (Korf, 2005).
To continue, the eﬀects of G. lucidum on cancer cells was
investigated (Sliva, 2006) and inhibition of proliferation
and apoptosis was observed in leukemia, lymphoma, and
myeloma cells. Moreover, the inhibition of acute myolob-
lastic leukemia cells was associated with cell cycle arrest
and apoptosis, whereas the inhibition of lymphoma was
mediated by the upregulation of expression. G. lucidum
inhibits distinct signalling pathways in diﬀerent cancer
cells. Finally, standardized G. lucidum extracts containing
0.15% ganoderic acid C2 were used. However, it is uncer-
tain if this amount of ganoderic acid could be responsible
for the eﬀect on haematopoietic cells. Finally, the composi-
tion and amount of biologically active triterpenes depend
on the places of production, cultivation conditions, extrac-
tion procedures and the strains of G. lucidum.
Extracts of G. lucidum inhibited markedly intracellular
signalling and invasive behaviour of cancer cells, whereas
others did not. This complexity can also bring signiﬁcant
advantages. For example, certain components in the natu-
ral products can reduce the cytotoxicity of the whole prod-
uct (and vice versa – my addition). Also, the interaction
between diﬀerent biologically active components can be
responsible for their eﬀects in vivo. Diﬀerent compounds
can modulate unrelated signalling and therefore, can pos-
sess synergistic eﬀects (see Aydemir, 2002). Thus, triter-
penes in G. lucidum suppress growth and invasive
behaviour of cancer cells, whereas the polysaccharides
stimulate the immune system resulting in the production
of cytokines and activation of anti-cancer activities of
immune cells (Sliva, 2006).
In summary, the organism inhibits (a) proliferation and
invasive behaviour of breast and prostate cancer cells; (b)
growth and induces apoptosis of breast and prostate cancer
cells; (c) growth of hepatoma cells; and (d) secretion of vas-
cular endothelial growth factor suppressing angiogenesis
and transforming growth factor from prostate cancer cells.
In addition, it induces apoptosis of colon cancer cells
(Sliva, 2006). Stanley et al. (2005) demonstrated that G.
lucidum induces apoptosis, inhibits cell proliferation, and
suppresses cell migration of human prostate cancer cells.
However, the molecular mechanism(s) has not been fully
elucidated.
G. lucidum may have an immuno-modulating eﬀect in
patients with advanced colorectal cancer (Chen et al.,
2006). Further studies are needed to explore the beneﬁts
and safety to cancer patients. In addition, there is further
evidence of G. lucidum inhibiting prostate cancer cell prolif-
eration (Johnston, 2005). Pero et al. (2005) report on a
combination of mushroom extracts (Cordyceps sinensis,
R. Russell M. Paterson / Phytochemistry 67 (2006) 1985–2001 1993Grifola blazei, Gr. frondosa, Trametes versicolor and G. luci-
dum) into a formulation designed to optimise diﬀerent
modes of immunostimulatory action, and yet that would
avoid metabolic anti-oxidant competition. Less than
expected eﬃcacious eﬀects were obtained. However,
despite this, the data were taken as strong evidence that
the combination gave additive or synergistic eﬀects to
health. Furthermore, an extract from G. lucidum was
screened by Mu¨ller et al. (2006) for anti-proliferative activ-
ity using a human cancer cell line. The results indicated
that G. lucidum had a profound activity against leukemia,
lymphoma and multiple myeloma cells and may be a novel
adjunctive therapy for the treatment of haematologic
malignancies. Kuo et al. (2006) obtained supportive evi-
dence for the eﬀect of dried mycelium of G. lucidum on
the enhancement of innate immune response. Lin et al.
(2006) investigated the eﬀects of two G. tsugae supplement
products and the results suggest that supplementation diets
might alleviate bronchoalveolar inﬂammation via decreas-
ing the inﬁltration of inﬂammatory cells and the secretion
of inﬂammatory mediators into the lungs and airways.
Overall, the results indicated a therapeutic application for
G. tsugae in allergic asthma.
To continue, a methanol extract of G. lucidum demon-
strated the strongest 5a-reductase inhibitory activity
among 19 edible and medicinal mushrooms (Noguchi
et al., 2005). A clinical trial was conducted to evaluate
the safety and eﬃcacy of the extract in men with mild
symptoms of bladder outlet obstruction and signiﬁcant
reductions in the problem were observed. The extract ofTable 2
General compounds and eﬀects of Ganoderma reported in the literature until
Compound Eﬀect
Adenosine Antiplatelet aggregation
Lectins Mitogenic
Polysaccharides Antiﬁbriotic
Antiherpetic
Anti-inﬂammatory
Hepatoprotective
Hypoglycaemic
Immuno-modulatory – anti-tumour
Miscellaneous (radiation protection
DNA damage, anti-oxidant)
Protein (‘‘LZ-8’’) Immunodulatory
Immunosuppressive
Terpenoids and related compounds Anti-bacterial
‘‘Anti-complement’’
Anti-inﬂammatory
Anti-oxidant
Antiplatelet aggregation
Antiviral
Cytotoxicity
Enzyme inhibitors
Hepatoprotective
Hypolipidemic (chloresterol inhibito
HypotensiveG. lucidum was well tolerated. Fujita et al. (2005) investi-
gated the inhibitory eﬀects of methanol extracts of 19 edi-
ble and medicinal mushrooms on 5a-reductase activity (see
also Noguchi et al., 2005). The extract of G. lucidum Fr.
Krast showed the strongest inhibitory activity. The treat-
ment of the fruit body of the fungus or the extract prepared
from it inhibited signiﬁcantly the testosterone-induced
growth of the ventral prostate in castrated rats. These
results showed that G. lucidum might be a useful ingredient
for the treatment of benign prostatic hyperplasia. Presum-
able the extracts were similar to those reported by Mau
et al. below.
G. tsugae was available in the form of mature and baby
Ling chih (note diﬀerent spelling and construction), myce-
lia and fermentation ﬁltrate (Mau et al., 2005a). The term
‘‘baby’’ is of course unscientiﬁc. From methanolic extracts
the mature and baby Ling chih demonstrated high anti-oxi-
dant properties. Total phenols were the major naturally
occurring anti-oxidant components found in all extracts
and in the range of 24.0–35.6 mg g1. Therefore phenols
may not be the active component as the mycelium and ﬁl-
trate were inactive. In hot water extracts from the same
high anti-oxidant activities were again obtained (Mau
et al., 2005b). At 20 mg/ml, the scavenging abilities on
hydroxyl radicals were in the descending order of Ling
chih > baby Ling chih > mycelia > ﬁltrate. Again total
phenols were the major naturally occurring anti-oxidant
components found in hot water extracts and in the range
of 40.86–42.34 mg/g. From EC50 values obtained, fruit
bodies of G. tsugae (Ling chih and baby Ling chih) were2004
Reference
Kawagishi et al. (1993), Shimizu et al. (1985)
Ngai and Ng (2004)
Park et al. (1997)
Eo et al. (1999a,b, 2000), Kim et al. (2000), Oh et al. (2000)
Ukai et al. (1983)
Zhang et al. (2002)
Hikino et al. (1985, 1989), Hikino and Mizuno (1989),
Tomoda et al. (1986), Zhang and Lin (2004)
Gao et al. (2000a,b), Li et al. (2000), Li and Zhang (2000),
Ooi et al. (2002), Sasaki et al. (1971), Sone et al. (1985)
, Kim and Kim (1999b), Lee et al. (2001)
van der Hem et al. (1995)
van der Hem et al. (1995)
Smania et al. (1999)
Min et al. (2001)
Kleinwa¨chter et al. (2001)
Zhu et al. (1999)
Shiao (1992)
El-Mekkawy et al. (1998), Mothana et al. (2003)
Gao et al. (2002), Gonzalez et al. (2002), Kimura et al. (2002),
Lin et al. (1991), Su et al. (2000), Wu et al. (2001)
Lee et al. (1998)
Chen and Yu (1999), Kim et al. (1999)
rs) Komoda et al. (1989), Shiao (1992)
Morigiwa et al. (1986)
1994 R. Russell M. Paterson / Phytochemistry 67 (2006) 1985–2001‘‘good’’ in anti-oxidant properties, except for the chelating
ability on ferrous ions. It is clear that the methanol and
aqueous extracts were similar and one wonders why two
papers were required to reveal this.
Lu et al. (2004) detected the chemo-preventive eﬀects of
G. lucidum using a unique in vitro human urothelial cell
(HUC) model consisting of HUC-PC and other cells. Eth-
anol and water extracts of basidiocarps and spores of the
G. lucidum were used. Results indicated that ethanol
extracts had a stronger growth inhibition eﬀect than water
extracts. At non-cytotoxic (see Table 2) concentrations
(40–80 lg/ml), these extracts induced actin polymerization,
which in turn inhibited carcinogen 4-aminobiphenyl
induced migration in both cell lines. Again there may be
similarity in chemical composition to the extracts men-
tioned previously. In conclusion, preclinical and clinical
studies are necessary for the validation of this natural prod-
uct in the prevention and/or therapy of cancer (Sliva, 2006)
and other applications. Also, the eﬀects of isolated com-
pounds require to be tested further as discussed
subsequently.6. Pure chemicals and biomedical applications
Gao et al. (2003) reviewed the ‘‘antiviral value’’ of the
genus Ganoderma, which provided the major biologically
active constituents and their eﬀect or mode of action. The
anti-cancer eﬀects of G. lucidum were associated with triter-
penes, polysaccharides, (and)/or immuno-modulatory pro-
teins, via inhibition of DNA polymerase, inhibition of
post-translational modiﬁcation of the Ras oncoprotein,
or the stimulation of cytokine production (Sliva, 2006).
Active components of the fungus have been discovered in
(a) liquid cultivated mycelia (Gao et al., 2000b), (b) culture
medium (Song et al., 1998; Tasaka et al., 1988a) and (c) the
spores (Min et al., 2001). Basidiocarps are well known to
contain active compounds. A list of the biological activities
and broad chemical groupings is provided in Table 2.
6.1. Triterpenoids and sterols
Terpenoids are comprised of four groups: the (a) volatile
mono- and sesquiterpenes (essential oils) (C10 and C15),
(b) less volatile diterpenes (C20), (c) involatile triterpenoids
and sterols (C30), and (d) the carotenoid pigments (C40).
Most investigations on Ganoderma concern the less volatile
triterpenoid (triterpene) and sterol forms although there
appears to be some confusion over names (see Lindequist,
1995). Increasingly other species to G. lucidum are now
being investigated for triterpenoids and steroids. Kim and
Kim (1999a) have summarised structural relationships in
G. lucidum. The triterpene chemical structure is based on
that of lanosterol, an important intermediate. Structural
diversity is brought about by stereochemical rearrange-
ments of this seminal compound. The physicochemical
properties of over 130 lanostane-type triterpenoids havebeen described (Kim and Kim, 1999a) since ganodermic
acid A and B were ﬁrst described. The bitter components
of ‘‘Lingzhi’’ are triterpenes/triterpenoids and have known
pharmacological activities (Table 2; Huie and Di, 2004).
Interestingly, Nishitoba et al. (1986) suggested that tri-
terpenes were speciﬁc to G. lucidum. However, they have
been recorded subsequently in the following ‘‘species’’: G.
colossum, G. applanatum, an unidentiﬁed Ganoderma sp.,
G. tsugae, G. concinna, G. tropicum and G. pfeiﬀeri (Rob-
erts, 2004). This indicates strongly that they are more clo-
sely related than ﬁrst considered. The isolation of
triterpenes from basidiocarps has been very well docu-
mented. Many have indicated biological activity as anti-
tumour and antiviral agents: Spores are also sources. In
fact, there are indications that spores have higher concen-
trations of ganoderic alcohols and acids than basidiocarps
(Min et al., 1998). Cultivated mycelium has been reported
to contain similar compounds (Lin et al., 2003).
Triterpenes are considered to be potential anti-cancer
agents due to activity against growing tumours (Lin
et al., 2003): they have direct cytotoxicity against tumour
cells (Gonzalez et al., 2002) rather than enhancing the
immune system as do polysaccharides. Basidiocarps of G.
lucidum contain unique intensely-bitter compounds that
may be related to activity (Mizuno, 1997). Furthermore,
triterpenes inhibited HIV-1 protease (Min et al., 1998)
and HIV-2 protease (El-Mekkawy et al., 1998). Hepatopro-
tective mechanisms of ganosporeric acid A from the spores
of G. lucidum were observed by Chen and Yu (1999).
Also, triterpenoids from the basidiocarps of G. lucidum
and G. applanatum, and malonate half-esters from the same
Ganoderma species inhibitor tumour promotion (Chairul
et al., 1991; Lin et al., 1991). However, and importantly,
some esters showed toxicity at high concentrations (Chai-
rul et al., 1990).
Su et al. (2000) examined the cytotoxic activity of lano-
stanoids from G. tsugae and found activity against three
cancer cell lines. Lanostanoid and a sterol from G. tsugae
caused cell death by apoptosis and suggested that it was
the sterol that possessed the cell cycle inhibition activity
(Gan et al., 1998a). Gonzalez et al. (2002) also observed
apoptosis in human promyelocytic leukaemia HL-60 cells
exposed to three lanostanoids isolated from G. concinna.
In contrast, three triterpenoids from G. concinna inhibited
calf and rat DNA polymerases implicated in DNA repair,
recombination and DNA replication (Mizushina et al.,
1999). Two terpenes, lucidenic acid O and lucidenic lac-
tone, inhibited the HIV type 1 reverse transcriptase. Two
cerebrosides from G. lucidum inhibited selectively the activ-
ities of replicative DNA polymerases in mammals (Mizush-
ina et al., 1998) but had little eﬀect on other polymerases,
transferases, HIV reverse transcriptase, RNA polymerase,
deoxyribonuclease I and ATPase. Morigiwa et al. (1986)
observed that a methanol extract from the fruiting body
of G. lucidum inhibited angiotensin-converting enzyme
involved in the control of hypertension. The extract con-
tained ten lanostane triterpenes, of which eight exhibited
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induced platelet aggregation by stimulating the hydrolysis
of phosphatidylinositol 4,5-bisphosphate (Shiao, 1992).
From these, and the more recent work reported below, it
is known now that triterpenes possess bioactivities, such
as anti-oxidation, hepatoprotection, anti-allergy, anti-
hypertension, cholesterol reduction, and inhibiting platelet
aggregation. The eﬀects are from inhibition of enzymes
such as galactosidase, angiotension converting enzyme,
cholesterol synthase, etc. (Huie and Di, 2004).
Hajjaj et al. (2005) report the isolation and identiﬁcation
of the 26-oxygenosterols ganoderol A, ganoderol B, ganod-
eral A, and ganoderic acid Y and they determined that the
point of inhibition of cholesterol synthesis is between
lanosterol and lathosterol. Interestingly, the 26-oxygenos-
terols could lead to novel therapeutic agents that lower
blood cholesterol. Timo et al. (2005) isolated four sterols
and 10 triterpenes from the fruiting bodies of G. pfeiﬀeri,
including the three new triterpenes: lucialdehyde D, ganod-
erone A, and ganoderone C. Ganoderone A, lucialdehyde
B, (and ergosta-7,22-dien-3b-ol) were found to exhibit
potent inhibitory activity against herpes simplex virus.
Very signiﬁcant activity was established. Lanostanoid tri-
terpenes isolated from G. amboinense inhibited (a) the
growth of numerous cancer cell lines, and (b) the activities
of topoisomerases I and IIa (Li et al., 2005). One of the
most potent triterpene was ganoderic acid X (GAX). The
ability of GAX to inhibit topoisomerases and to sensitize
the cancer cells toward apoptosis fulﬁls the feature of a
potential anti-cancer drug. Liu et al. (in press) state that
the ethanol extract of G. lucidum demonstrated inhibitory
activity on both isozymes of 5a-reductase (see previously)
and suppression eﬀects of ventral prostate growth. Analysis
suggested that the active principles in vivo were triterpe-
noids. These results indicate that the triterpenoids fraction
of G. lucidum ‘‘might’’ be a useful ingredient in the treat-
ment of benign prostatic hyperplasia. As mentioned previ-
ously, G. lucidum extracts containing 0.15% ganoderic acid
C2 were used in demonstrating anti-cancer eﬀects. How-
ever, it is uncertain if this amount of ganoderic acid could
be responsible for the eﬀect. In addition, diﬀerent com-
pounds can modulate unrelated signalling and therefore,
can possess synergistic eﬀect. The diﬀering eﬀects of triter-
penes and polysaccharides are again noted.
In summary, recent research has demonstrated that: (1)
a triterpene fraction from the mycelia of G. lucidum inhib-
ited growth of human hepatoma cells, (2) the anti-oxidative
activities of G. lucidum extracts were examined and the tri-
terpene fraction (ganoderic acids A, B, C and D, lucidenic
acid B and ganodermanotriol) exhibited the highest eﬀect
by testing the ingredients against pyrogallol induced oxida-
tion on erythrocyte membrane and Fe(II)-ascorbic acid
induced lipid peroxidation in liver mitochondria, and (3)
triterpenes isolated from the spores of G. lucidum, such as
ganoderic acid, luciumol B, ganodermanodiol, ganoderm-
anontriol and ganolucidic acid, showed signiﬁcant anti-
HIV-1 protease activity.Sterols are related closely to triterpenoids and are found
in Ganoderma. The basidiocarps and mycelium and have
potent cytotoxic activity. Ergosterolperoxide, from G. luci-
dum enhances the inhibitory eﬀect of linoleic acid on mam-
malian DNA polymerase (Mizushina et al., 1998). The
eﬀect of Ganoderma total sterol (GS) and its main compo-
nents (GS1) on rat cortical neuronal cultures exposed to
hypoxia/reoxygenation (H/R) was studied in vitro (Zhao
et al., 2005) and the results suggest that GS might be useful
in treating H/R-induced oxidative stress and inﬂammatory
response. In addition, pre-treatment with GS1 signiﬁcantly
attenuated the decline of neuron viability and the forma-
tion of reactive oxygen species.
Anti-bacterial eﬀects include those from steroidal com-
pounds from the basiciocarps of G. applanatum, which
were found to have broad spectrum activities and bacteri-
cidal eﬀects (Smania et al., 1999). Ganomycins A and B,
from G. pfeiﬀeri exhibited anti-bacterial activity against
Gram-negative and Gram-positive bacteria (Mothana
et al., 2000). Sterols (Komoda et al., 1989) and oxygenated
triterpenes (Shiao, 1992) have been shown to inhibit choles-
terol synthesis in vitro.
6.2. Polysaccharides
Polysaccharides represent a structurally diverse class of
biological macromolecules with a wide-range of physico-
chemical properties. The major bioactive Ganoderma poly-
saccharides species are b-1-3 and b-1-6-D glucans. The
structure is b-1-3 D-glucopyronan with 1–15 units of b-1-
6 monoglucosyl side chains.
Alternative anti-tumour compounds are glycoproteins
(polysaccharides and proteins), heteropolysaccharides and
ganoderans A, B and C (Lindequist, 1995). They have high
molecular weights as a common feature which tends to
increase water solubilities and result in more eﬀective
anti-tumour activity. However, some water insoluble poly-
saccharides also possess anti-tumour activity (Wang et al.,
1993) and polysaccharide branching aﬀects activity. Scien-
tiﬁc investigations concerning the anti-tumour and
immuno-modulating activities of G. lucidum were reported
as early as in 1957 and, more recently, extensive studies on
the anti-tumour ingredient(s), especially polysaccharides
and protein/peptide bound polysaccharides, have been car-
ried out. For example, several glucans that were isolated in
the early 1980s from water and alkali extracts were found
to be bioactive.
Bioactive polysaccharides have been isolated from the
basidiocarps (Bao et al., 2002; Zhang and Lin, 2004) and
from the mycelial biomass cultivated in liquid culture
(Kim et al., 1993). Few have been isolated from the culture
medium (Kim et al., 2003). Importantly, the water soluble
polysaccharides of G. lucidum inhibited strongly the growth
of Sarcoma 180 solid-type tumour, with an inhibition ratio
of greater than 95%. Most of the anti-tumour glucans were
reported to contain a branched glucan core and an average
molecular weight of 1,050,000 Da. Polysaccharides are
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enhancement of host-mediated immunity rather than a
direct cytotoxicity to the tumour cells. It should be noted
that the amount of bioactive water-insoluble polysaccha-
rides was found to be higher than that of water-soluble
polysaccharides. More than 200 polysaccharides have been
isolated from the fruiting bodies, spores, mycelia and culti-
vation broth of ‘‘Lingzhi’’ (Huie and Di, 2004).
In addition, polysaccharides from G. lucidum demon-
strated activity (Kim et al., 1999; Zhang et al., 2002). Sim-
ilar fractions from G. lucidum exhibited activity against
HSV-1 and HSV-2 (Eo et al., 1999b, 2000; Kim et al.,
2000; Oh et al., 2000). Unsurprisingly, high concentrations
can be immunosuppressive and so it would be important to
use safe concentrations for any proposed treatment.
Fractions from G. lucidum have been shown to inhibit
tumour growth through activation of host-mediated
immune responses by stimulating the production of induc-
ing cytokines (or cytotoxic T lymphocytes) from mononu-
clear leukocytes (Lieu et al., 1992) and promoting the
production of interleukin 2 (Lei and Lin, 1992; Ooi et al.,
2002). The activity and mechanism of these polysaccha-
rides was a major area of research at that time. It has also
been observed that the host mediated anti-tumour eﬀect is
increased by the attachment of polyol groups to glucans
(Sone et al., 1985). Anti-tumour activity against trans-
planted Sarcoma 180 in mice has been exhibited by the
b-D-glucan polysaccharides from the basidiocarps of
G. applanatum (Sasaki et al., 1971), G. lucidum (Sone et al.,
1985) and the culture ﬂuid of G. lucidum (Sone et al.,
1985). Ooi et al. (2002) also observed the suppression of
growth of Sarcoma 180 solid tumour in mice and a marked
increase in the expression levels of immuno-modulatory
cytokines in the presence of a hot-water-extracted G. luci-
dum polysaccharide. In contrast, there was no cytotoxic
eﬀect observed for a water-insoluble glucan from G. japon-
icum (Ukai et al., 1983) or for the mycelial extract from
G. lucidum on oral tumour cells in vitro (Chen et al., 1991).
Six water-soluble polysaccharides were extracted
sequentially from the mycelium of G. tsugae (Peng et al.,
2005). They were heteropolysaccharide–protein complexes.
GTM3 and GTM4 contained (1! 3)-b-D-glucans and
(1! 4)-a-D-glucans, while GTM5 and GTM6 were mainly
a (1! 6)-branched (1! 3)-b-D-glucan. With the progress
of isolation, the content of a fraction decreased from
90.2% to 57.1%, and accompanied with enhanced anti-
tumour activity. The polysaccharides GTM1, GTM2 and
GTM3 had signiﬁcantly higher anti-tumour activity
against solid tumour Sarcoma 180 with an inhibition ratio
higher than 50%. The results suggested that the eﬀects on
the improvement of anti-tumour activities of polysaccha-
rides ‘‘could not be negligible’’. Polysaccharides have been
shown to enhance the activity of DNA polymerases (Lei
and Lin, 1993). These authors observed the activity of
DNA polymerase to increase in the splenocytes of mice,
after they had administered intraperitoneally Ganoderma
polysaccharides (GL-B).Zhang and Lin (2004) and Hikino et al. (1985) observed
that polysaccharides from the basidiocarps of G. lucidum
possessed a hypoglycaemic eﬀect in mice. However, studies
by Tomoda et al. (1986) found that they were not glycans
but peptidoglycans. An unusual report is available on a
chitin membrane used as a wound dressing known as ‘‘sac-
chachitin’’and developed from the residue of the fruiting
body of G. tsugae (Su and Hsu, 1995).
In the most recent reports, Chen et al. (2006) present
results indicating that G. lucidum may have potential
immuno-modulating eﬀect in patients with advanced colo-
rectal cancer. More recent research into polysaccharides
includes:
(1) Water soluble polysaccharides extracted from G. luci-
dum were eﬀective in preventing DNA from strand
breakage indicating the anti-tumour and immuno-
modulating activities of ‘‘Lingzhi’’ are strongly
related to its anti-oxidative property.
(2) The anti-oxidant property of Ganoderma polysaccha-
ride peptide decreased the oxidation of low density
lipoprotein and exhibited anti-oxidant eﬀect by scav-
enging reactive oxygen species in mice.
(3) A proteoglycan having a carbohydrate/protein ratio
of 11.5 to 1 – isolated from G. lucidum, was found
to stimulate the proliferation of mouse spleen lym-
phocytes, resulting in a three to fourfold increase in
the (a) percentage of B cells, (b) secretion of immuno-
globulin, (c) production of interleukin 2 and (d)
expression of protein kinase.
(4) It was found that the polysaccharide extracts from
the mycelium of G. lucidum exhibited anti-tumour
eﬀects against ﬁbrosarcoma in male and female mice
and inhibited the metastasis of a tumour to the lung.
The bioactive polysaccharides could stimulate blood
mononuclear cells to increase cytokines, tumour
necrosis factor, interferon and interleukin produc-
tion, and the lifespan of tumour-implanted mice
was found to increase signiﬁcantly due to the admin-
istration of GLP.
(5) Two protein bound polysaccharides, a neutral pro-
tein bound polysaccharide (NPBP) and an acidic pro-
tein bound polysaccharide (APBP), were isolated
from water soluble substances of G. lucidum APBP
was found to be more potent than NPBP as an anti-
viral agent against herpes simplex viruses (HSV). The
antiviral activity of APBP appeared to be related to
its binding with HSV-speciﬁc glycoprotein at the cell
membrane (Huie and Di, 2004). G. lucidum polysac-
charides (Gl-PS) have shown a variety of immune
modulating eﬀects. Results conﬁrmed that Gl-PS
was a promising biological response modiﬁer and
immune potentiator (Zhu and Lin, 2006).
The extraction procedures for polysaccharides involve
standard methodology (see Huie and Di, 2004). However,
the extraction of water insoluble polysaccharides from
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tion. This method is based on the attack of the enzyme on
the polysaccharide substrates, composed of cellulose and
lignin. However, lignin in the fungal preparation is very
surprising and is probably a false assumption. This may
have arisen from referring to the fungi as herbs as they
may contain lignin. For information, it has been reported
that enzyme hydrolysis reaction can be enhanced by ultra-
sonic waves.
6.3. Proteins, peptides and amino acids
Bioactive proteins have been isolated from various
‘‘Lingzhi’’ species and characterized by chromatographic/
electrophoretic techniques. For example, a new immuno-
modulatory protein, known as Ling Zhi-8 (LZ-8), was iso-
lated from the mycelia of G. lucidum. LZ-8 is a polypeptide
consisting of 110 amino acid residues with an acetylated
amino terminus and has a molecular mass of 12 kDa
(Tanaka et al., 1989). Mitogenic activity and also has been
reported (e.g. van der Hem et al., 1995).
Ngai and Ng (2004) isolated a lectin from G. capense
that exhibited potent mitogenic activity toward mouse
splenocytes and anti-proliferative activity toward leukae-
mia cells and hepatoma cells in vitro. The lectin exhibited
more potent mitogenic activity than that of concanavalin
A. It was found that three kinds of bioactive proteins from
the fruiting body and spores of ‘‘Lingzhi’’ showed obvious
mitogenic activity. Proteins in the form of enzymes have
also been isolated and characterized by various types of
column chromatography as well as electrophoretic tech-
niques. For example, DEAE-Sephadex column (gel ﬁltra-
tion) and Con A-Sepharose (aﬃnity chromatography)
were employed for the puriﬁcation of galactosidase from
the fruiting body of G. lucidum. In addition, a variety of
amino acids have been found in Lingzhi. Oxidative stress
has been linked with the pathogenesis of many human dis-
eases including cancer, aging, and atherosclerosis (Sun
et al., 2004). Their study investigated the potent anti-oxi-
dant activities of peptides isolated from G. lucidum. Poly-
saccharides, polysaccharide–peptide complex (and
phenolic components) of G. lucidum have been proposed
to be responsible for this anti-oxidant eﬀect. However,
research has shown that the G. lucidum peptide is the major
anti-oxidant component. In another investigation of G.
lucidum polysaccharide peptide (Gl-PP) demonstrated
some eﬀects as anti-tumours compounds in mice and
potential anti-angiogenesis (Cao and Lin, 2006). They elu-
cidated the possible mechanism of Gl-PP action on anti-
angiogenesis of tumours. Inducing cell apoptosis by Gl-
PP might be the mechanism of inhibiting proliferation.
Human lung carcinoma cells when exposed to high dose
of Gl-PP in hypoxia for 18 h resulted in a decrease in an
important chemical indicator of cancer. Taken together,
these ﬁndings support the hypothesis that the key attribute
of the anti-angiogenic potential of Gl-PP is that it may
directly inhibit vascular endothelial cell proliferation orindirectly decrease growth factor expression of tumour
cells.
Wang and Ng (2006) isolated a 15-kDa antifungal pro-
tein, designated ganodermin, from G. lucidum. Ganoder-
min inhibited the mycelial growth of Botrytis cinerea,
Fusarium oxysporum and Physalospora piricola. However,
it was devoid of haemagglutinating, deoxyribonuclease,
ribonuclease and protease inhibitory activities.6.4. Nucleosides, nucleotides and RNAs
Yu and Zhai in an obscure journal (see Huie and Di,
2004) were the ﬁrst to report the isolation of adenine, aden-
osine, uracil and uridine from the mycelia of a Ganoderma
species, G. capense. Among these, nucleosides, uridine and
uracil were found to be capable of lowering the serum
aldolase level of mice suﬀering from experimental myoto-
nia. Adenosine has also been shown to inhibit platelet
aggregation (Shimizu et al., 1985). In contrast, Gau et al.
(1990) found that the administration of crude Ganoderma
extracts, known to have a high content of adenosine, had
no eﬀect on platelet aggregation in haemophiliac patients
who were HIV positive. An epimer of 5 0-deoxy-5 0-methyl-
sulphinyladenosine was found to inhibit platelet aggrega-
tion in vitro (Kawagishi et al., 1993). However, why these
compounds should be diﬀerent in any way than those from
other sources is not clear (to me).6.5. Alkaloids, vitamins, essential minerals, ﬂavours, and
fatty acids
The compounds cyclooctasulfur (Tasaka et al., 1988b)
and oleic acid (Tasaka et al., 1988a), isolated from the cul-
ture broth of G. lucidum, were both found to inhibit hista-
mine release which is an important activity for treatment of
inﬂammation, allergies, and anaphtlactic shock. The alka-
loids, choline and betaine were isolated from the spores
of G. lucidum. Furthermore, two novel pyrrole alkaloids
(ganoine and ganodine) and a novel purine alkaloid (gano-
derpurine) were discovered from the mycelia of G. capense.
Vitamins (including b-carotene) and essential elements
have been isolated from various ‘‘Lingzhi’’ ‘‘species’’.
Aroma compounds were detected from G. applanatum
which may have novel biotechnological applications. Over
120 volatile ﬂavour compounds, mostly alcohols, alde-
hydes, ketones, esters, and phenols, have been identiﬁed
(Huie and Di, 2004). Finally, very-long-chain fatty acids
with more than 23 carbon atoms have been reported in
G. applanatum at trace levels (1–2%).7. Toxicity
It is obvious that this issue has received little attention in
the literature, despite it being crucial for the success of any
proposed medical treatments. This may reﬂect a certain
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However, indications of toxicity are provided in Table 2.8. Conclusions
The ﬁrst thing to say is that the activity data on isolated
compounds mentioned herein is very convincing. This
review summarised important areas of investigation being
performed on Ganoderma species around the world, with
particular emphasis on chemicals of biomedical relevance.
There is abundant evidence that these are eﬀective, and
more clinical trials are now in order. Searching for other
secondary metabolites from Ganoderma may prove fruitful
especially if the taxonomy was usefully revised.
However, unlike ‘‘Western medicine’’ in which therapeu-
tic eﬀects usually derive from a single chemical substance
within the drugs, the pharmacologically activities of ‘‘her-
bal’’ medicines invariably arise from a mixture of ‘‘active’’
ingredients within the materials. In fact, in many cases,
the biological activities of the active components adminis-
trated or consumed alone were found to be lower than those
obtained from the original mixture of active ingredients
present in herbs, such as ‘‘Lingzhi’’. Thus, the combined,
synergistic eﬀects of a mixture of active components that
are present in ‘‘Lingzhi’’ on biological activities need to be
thoroughly assessed. A factor which is not considered by
those who appear to advocate using Ganoderma is the pos-
sibility of toxic components in the fungus and preparations,
and more work is required in this area. Some combinations
of compounds are more toxic than the individual parts
while others ‘‘potentiate’’ usually non-toxic compounds.
This is why a good chemotaxonomy is required of the genus
and employing the bioactive components for this purpose.
It is clear that many issues are raised of a systematic nature
– not least as they relate to ﬁnding fungi with active but not
toxic ingredients. Crucially, we need to know what the non-
Latinised names actually represent – past and present.
In the search for active compounds fromGanoderma spe-
cies, the majority of research has been performed on
extracts from the fruiting body and there have been fewer
studies on extracts from the liquid cultivated mycelium. It
appears that there are a number of biologically active com-
pounds to be found in the mycelium and the beneﬁts of
liquid cultivation over solid cultivation include: the ability
to manipulate the cultivation medium to optimise mycelial
growth; a shorter cultivation time; and less contamination.
In fact, the reason that some of theGanoderma preparations
are not yet available as medicines may be from diﬃculties
relating to mass production (Smith et al., 2002).Acknowledgement
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